Top

Published in:

01-01-2017 | Review on RMD

Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms

Authors: Kaitlyn M. Yim, April W. Armstrong

Published in: Rheumatology International | Issue 1/2017

Abstract

Psoriasis and psoriatic arthritis are associated with a significantly increased risk of cardiovascular risk factors and major adverse cardiovascular events (MACE). Active research is ongoing to elucidate this relationship between psoriatic diseases and cardiovascular comorbidities, as well as their shared pathogenic mechanisms. This review focuses on (1) the epidemiologic association between psoriasis and cardiovascular risk factors, (2) the epidemiologic association between psoriasis and MACE, (3) the epidemiologic association between psoriatic arthritis, cardiovascular risk factors, and MACE, and (4) proposed mechanisms for the contribution of psoriatic diseases to cardiovascular diseases. The proposed mechanisms for shared pathogenesis between psoriatic diseases and cardiovascular diseases are inflammation, insulin resistance, dyslipidemia, angiogenesis, oxidative stress, and endothelial dysfunction. There is complex interplay and overlap among these mechanisms and their contributions to shared pathogenesis. Future translational research is necessary to elucidate the link between psoriatic diseases and cardiovascular diseases. Such findings may be applied clinically to improve the lives of psoriasis patients.

Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512–516. doi:10.1016/j.jaad.2013.11.013 CrossRefPubMed

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2):377–385. doi:10.1038/jid.2012.339 CrossRefPubMed

Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 149(10):1173–1179. doi:10.1001/jamadermatol.2013.5015 CrossRefPubMedPubMedCentral

Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, Troxel AB (2009) The risk of stroke in patients with psoriasis. J Invest Dermatol 129(10):2411–2418. doi:10.1038/jid.2009.112 CrossRefPubMedPubMedCentral

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296(14):1735–1741. doi:10.1001/jama.296.14.1735 CrossRefPubMed

Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 31(8):1000–1006. doi:10.1093/eurheartj/ehp567 CrossRefPubMed

Armstrong EJ, Harskamp CT, Armstrong AW (2013) Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2(2):e000062. doi:10.1161/jaha.113.000062 CrossRefPubMedPubMedCentral

Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 163(3):586–592. doi:10.1111/j.1365-2133.2010.09941.x CrossRefPubMedPubMedCentral

Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ (2007) National psoriasis foundation clinical consensus on disease severity. Arch Dermatol 143(2):239–242. doi:10.1001/archderm.143.2.239 CrossRefPubMed

10.

Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55(5):829–835. doi:10.1016/j.jaad.2006.08.040 CrossRefPubMed

11.

Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, Troxel AB, Gelfand JM (2015) Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 151(2):161–169. doi:10.1001/jamadermatol.2014.2094 CrossRefPubMedPubMedCentral

12.

Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL (2011) Psoriasis and hypertension severity: results from a case-control study. PLoS One 6(3):e18227. doi:10.1371/journal.pone.0018227 CrossRefPubMedPubMedCentral

13.

Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, Skov L, Torp-Pedersen C, Ahlehoff O (2013) Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care 36(8):2402–2407. doi:10.2337/dc12-2330 CrossRefPubMedPubMedCentral

14.

Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM (2012) Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 132(3 Pt 1):556–562. doi:10.1038/jid.2011.365 CrossRefPubMed

15.

Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK (2011) Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 147(4):419–424. doi:10.1001/archdermatol.2010.370 CrossRefPubMed

16.

Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, Hsu MC, Yeilding N, Rader DJ, Mehta NN (2012) Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 67(1):76–85. doi:10.1016/j.jaad.2011.06.035 CrossRefPubMed

17.

Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H (2010) Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci 57(2):143–144. doi:10.1016/j.jdermsci.2009.11.002 CrossRefPubMed

18.

Ma C, Harskamp CT, Armstrong EJ, Armstrong AW (2013) The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 168(3):486–495. doi:10.1111/bjd.12101 CrossRefPubMed

19.

Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY (2009) Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 60(2):225–230. doi:10.1016/j.jaad.2008.09.046 CrossRefPubMed

20.

Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM (2008) Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 144(12):1571–1575. doi:10.1001/archderm.144.12.1571 CrossRefPubMed

21.

Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J (2008) Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology (Basel, Switzerland). doi:10.1159/000111512

22.

Ma C, Schupp CW, Armstrong EJ, Armstrong AW (2014) Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES). J Eur Acad Dermatol Venereol JEADV 28(8):1109–1112. doi:10.1111/jdv.12232 CrossRefPubMed

23.

Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, Abildstrom SZ, Skov L, Torp-Pedersen C, Hansen PR (2011) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270(2):147–157. doi:10.1111/j.1365-2796.2010.02310.x CrossRefPubMed

24.

Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156(2):271–276. doi:10.1111/j.1365-2133.2006.07562.x CrossRefPubMed

25.

Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ (2012) Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 109(7):976–980. doi:10.1016/j.amjcard.2011.11.025 CrossRefPubMed

26.

Ahlehoff O, Gislason GH, Lindhardsen J, Olesen JB, Charlot M, Skov L, Torp-Pedersen C, Hansen PR (2011) Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med 270(3):237–244. doi:10.1111/j.1365-2796.2011.02368.x CrossRefPubMed

27.

Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, Gelfand JM (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. doi:10.1016/j.amjmed.2011.03.028 PubMedCentral

28.

Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74(2):326–332. doi:10.1136/annrheumdis-2014-205675 CrossRefPubMed

29.

Parisi R, Rutter MK, Lunt M, Young HS, Symmons DP, Griffiths CE, Ashcroft DM (2015) Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 135(9):2189–2197. doi:10.1038/jid.2015.87 CrossRefPubMed

30.

Armstrong AW, Harskamp CT, Armstrong EJ (2012) The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2:e54. doi:10.1038/nutd.2012.26 CrossRefPubMedPubMedCentral

31.

Armstrong AW, Harskamp CT, Armstrong EJ (2013) The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. doi:10.1097/HJH.0b013e32835bcce1 PubMed

32.

Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 149(1):84–91. doi:10.1001/2013.jamadermatol.406 CrossRefPubMed

33.

Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 68(4):654–662. doi:10.1016/j.jaad.2012.08.015 CrossRefPubMed

34.

Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH (2013) Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133(10):2340–2346. doi:10.1038/jid.2013.149 CrossRefPubMed

35.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69(5):729–735. doi:10.1016/j.jaad.2013.07.023 CrossRefPubMed

36.

Armstrong AW, Schupp C, Bebo B (2012) Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003–2011. Dermatology (Basel, Switzerland). doi:10.1159/000342180

37.

Favarato MH, Mease P, Goncalves CR, Goncalves Saad C, Sampaio-Barros PD, Goldenstein-Schainberg C (2014) Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol 32(2):182–187PubMed

38.

Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, Ogdie A, Gelfand JM, Choi HK (2014) Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford, England). doi:10.1093/rheumatology/ket343

39.

Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, Choi HK (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273–1277. doi:10.1136/annrheumdis-2012-201299 CrossRefPubMedPubMedCentral

40.

Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, Rosen CF, Gladman DD (2013) The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis 72(5):715–720. doi:10.1136/annrheumdis-2012-201497 CrossRefPubMed

41.

Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 63(12):1729–1735. doi:10.1002/acr.20627 CrossRef

42.

Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC (2011) A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 20(7):544–549. doi:10.1111/j.1600-0625.2011.01308.x CrossRefPubMed

43.

Wang Y, Gao H, Loyd CM, Fu W, Diaconu D, Liu S, Cooper KD, McCormick TS, Simon DI, Ward NL (2012) Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol 132(8):2067–2075. doi:10.1038/jid.2012.112 CrossRefPubMedPubMedCentral

44.

Ward NL, Umetsu DT (2014) A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J Invest Dermatol 134(9):2305–2307. doi:10.1038/jid.2014.216 CrossRefPubMedPubMedCentral

45.

Golden JB, Groft SG, Squeri MV, Debanne SM, Ward NL, McCormick TS, Cooper KD (2015) Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation. J Immunol (Baltimore, Md 1950). doi:10.4049/jimmunol.1402307

46.

Ziats NP, Robertson AL Jr (1981) Effects of peripheral blood monocytes on human vascular cell proliferation. Atherosclerosis 38(3–4):401–410CrossRefPubMed

47.

Jiang Y, Beller DI, Frendl G, Graves DT (1992) Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol (Baltimore Md: 1950) 148(8):2423–2428

48.

Chen YL, Chang YJ, Jiang MJ (1999) Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits. Atherosclerosis 143(1):115–123CrossRefPubMed

49.

Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D (1991) Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88(12):5252–5256CrossRefPubMedPubMedCentral

50.

Liu XL, Zhang PF, Ding SF, Wang Y, Zhang M, Zhao YX, Ni M, Zhang Y (2012) Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice. PLoS One 7(3):e33497. doi:10.1371/journal.pone.0033497 CrossRefPubMedPubMedCentral

51.

Rose S, Dave J, Millo C, Naik HB, Siegel EL, Mehta NN (2014) Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the psoriasis atherosclerosis and cardiometabolic disease initiative. Arthritis Res Ther 16(4):R161. doi:10.1186/ar4676 CrossRefPubMedPubMedCentral

52.

Rose S, Sheth NH, Baker JF, Ogdie A, Raper A, Saboury B, Werner TJ, Thomas P, Vanvoorhees A, Alavi A, Torigian DA, Gelfand JM, Mehta NN (2013) A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. Am J Cardiovasc Dis 3(4):273–278PubMedPubMedCentral

53.

Mehta NN, Li K, Szapary P, Krueger J, Brodmerkel C (2013) Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med 11:194. doi:10.1186/1479-5876-11-194 CrossRefPubMedPubMedCentral

54.

Takeshita J, Mohler ER, Krishnamoorthy P, Moore J, Rogers WT, Zhang L, Gelfand JM, Mehta NN (2014) Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc 3(1):e000507. doi:10.1161/jaha.113.000507 CrossRefPubMedPubMedCentral

55.

Li RC, Krishnamoorthy P, DerOhannessian S, Doveikis J, Wilcox M, Thomas P, Rader DJ, Reilly MP, Van Voorhees A, Gelfand JM, Mehta NN (2014) Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol 39(1):19–24. doi:10.1111/ced.12250 CrossRefPubMed

56.

Rose S, Stansky E, Dagur PK, Samsel L, Weiner E, Jahanshad A, Doveikis J, Naik HB, Playford MP, McCoy JP, Mehta NN (2014) Characterization of immune cells in psoriatic adipose tissue. J Transl Med 12:258. doi:10.1186/s12967-014-0258-2 CrossRefPubMedPubMedCentral

57.

Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, Boehncke WH (2007) Psoriasis patients show signs of insulin resistance. Br J Dermatol 157(6):1249–1251. doi:10.1111/j.1365-2133.2007.08190.x CrossRefPubMed

58.

Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011) The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20(4):303–307. doi:10.1111/j.1600-0625.2011.01261.x CrossRefPubMed

59.

Buerger C, Richter B, Woth K, Salgo R, Malisiewicz B, Diehl S, Hardt K, Boehncke S, Boehncke WH (2012) Interleukin-1beta interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol 132(9):2206–2214. doi:10.1038/jid.2012.123 CrossRefPubMed

60.

Schluter K, Diehl S, Lang V, Kaufmann R, Boehncke WH, Burger C (2015) Insulin resistance may contribute to upregulation of adhesion molecules on endothelial cells in psoriatic plaques. Acta Derm Venereol. doi:10.2340/00015555-2227

61.

National Institutes of Health NH, Lung, and Blood Institute (2016) How is high blood cholesterol diagnosed? http://www.nhlbi.nih.gov/health/health-topics/topics/hbc/diagnosis. Accessed 1 Apr 2016

62.

Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, VanVoorhees A, Gelfand JM (2012) Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 224(1):218–221. doi:10.1016/j.atherosclerosis.2012.06.068 CrossRefPubMedPubMedCentral

63.

Yu Y, Sheth N, Krishnamoorthy P, Saboury B, Raper A, Baer A, Ochotony R, Doveikis J, Derohannessian S, Voorhees AS, Torigian DA, Alavi A, Gelfand JM, Mehta NN (2012) Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis 2(4):285–292PubMedPubMedCentral

64.

Salahuddin T, Natarajan B, Playford MP, Joshi AA, Teague H, Masmoudi Y, Selwaness M, Chen MY, Bluemke DA, Mehta NN (2015) Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J. doi:10.1093/eurheartj/ehv339 PubMedPubMedCentral

65.

Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC (2011) Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 63(1):1–9. doi:10.1016/j.jdermsci.2011.04.007 CrossRefPubMed

66.

Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW (2014) Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20(4):513–528CrossRefPubMed

Title: Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms
Authors: Kaitlyn M. Yim
April W. Armstrong
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 1/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-016-3487-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk

Lipid profile among girls with systemic lupus erythematosus

Prolonged Tpeak–Tend interval in anti-Ro52 antibody-positive connective tissue diseases

Takayasu arteritis (TA) first presenting with intestinal ischemia: a case report and review of gastrointestinal tract involvement (ischemic and non-ischemic) associated with TA

Relationship between cigarette smoking and hyperuricemia in middle-aged and elderly population: a cross-sectional study

Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage